/HALO
Halozyme Therapeutics, Inc.
HALO • NASDAQHALO • NASDAQ • Healthcare
$63.70+0.22%+0.14
$63.70+0.22%(+0.14)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
79Low Risk
Momentum
29Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
78.1%▼6.2pp
Revenue after COGS
Operating
58.4%▲4.1pp
After operating expenses
Net
22.7%▼21.0pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
25.5
Price vs earnings
EV/EBITDA
8.8
Enterprise value
FCF Yield
8.0%
Cash generation
Earnings Yield
3.9%
Inverse of P/E
Capital Efficiency
209
GoAI Quality ScoreExcellent
⚠High Leverage Risk
Large ROE-ROA gap with weak interest coverage suggests the high returns are fueled by excessive debt rather than operational efficiency.
ROEReturn on Equity
649.2%Strong
ROAReturn on Assets
12.5%Strong
ROICReturn on Invested Capital
23.6%Strong
Financial Health
Current RatioHealthy
4.66
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-0.15x
Debt repayment capacity (<3x)
Income QualityStrong
2.06
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.25M | $660.12M | $443.31M |
| Gross Profit | $1.09B | $855.91M | $636.89M | $520.81M | $361.90M |
| Gross Margin | 78.1% | 84.3% | 76.8% | 78.9% | 81.6% |
| Operating Income | $816.29M | $551.48M | $337.57M | $267.53M | $275.90M |
| Net Income | $316.89M | $444.09M | $281.59M | $202.13M | $402.71M |
| Net Margin | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% |
| EPS | $2.64 | $3.50 | $2.13 | $1.48 | $2.86 |
Average Price Target
$76.14▲ 19.5% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Halozyme Therapeutics, Inc., the average price target is $76.14, with a high forecast of $94.00 and a low forecast of $56.00. The average price target represents a 19.5% increase from the current price of $63.70.
Highest
$94.00
Average
$76.14
Lowest
$56.00
Rating Distribution
Strong Buy
0
0%
Buy
17
63%
Hold
9
33%
Sell
1
4%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Wells Fargo● Maintain
Equal Weight
2026-02-19Benchmark● Maintain
Buy
2026-02-19TD Cowen● Maintain
Buy
2026-01-08HC Wainwright & Co.● Maintain
Buy
2025-12-19HC Wainwright & Co.● Maintain
Buy
2025-11-28Goldman Sachs● Maintain
Neutral
2025-11-18Citizens● Maintain
Market Outperform
2025-11-04JP Morgan● Maintain
Neutral
2025-10-27Morgan Stanley● Maintain
Overweight
2025-10-20HC Wainwright & Co.● Maintain
Buy
2025-10-15Earnings History & Surprises
BEAT RATE
78%
Last 18 quarters
AVG SURPRISE
+5.9%
EPS vs Estimate
BEATS / MISSES
14/4
Last 18 quarters
LATEST EPS
$-0.24
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
-111.2%
$-0.24 vs $2.15
Q4 '25
+5.5%
$1.72 vs $1.63
Q3 '25
+25.2%
$1.54 vs $1.23
Q2 '25
+16.8%
$1.11 vs $0.95
Q1 '25
+7.7%
$1.26 vs $1.17
Q4 '24
+29.6%
$1.27 vs $0.98
Q3 '24
+19.7%
$0.91 vs $0.76
Q2 '24
+12.9%
$0.79 vs $0.70
Q1 '24
-1.2%
$0.82 vs $0.83
Q4 '23
+5.6%
$0.75 vs $0.71
Q3 '23
+17.5%
$0.74 vs $0.63
Q2 '23
-2.1%
$0.47 vs $0.48
No investor questions available.
Latest News
No news available